263 related articles for article (PubMed ID: 15284314)
1. Cost-effectiveness of organized versus opportunistic cervical cytology screening in Hong Kong.
Kim JJ; Leung GM; Woo PP; Goldie SJ
J Public Health (Oxf); 2004 Jun; 26(2):130-7. PubMed ID: 15284314
[TBL] [Abstract][Full Text] [Related]
2. Clinical and cost implications of new technologies for cervical cancer screening: the impact of test sensitivity.
Hutchinson ML; Berger BM; Farber FL
Am J Manag Care; 2000 Jul; 6(7):766-80. PubMed ID: 11067374
[TBL] [Abstract][Full Text] [Related]
3. De novo establishment and cost-effectiveness of Papanicolaou cytology screening services in the Socialist Republic of Vietnam.
Suba EJ; Nguyen CH; Nguyen BD; Raab SS;
Cancer; 2001 Mar; 91(5):928-39. PubMed ID: 11251944
[TBL] [Abstract][Full Text] [Related]
4. [Cost effectiveness of cervical cancer screening strategies in Tunisia].
Hsaïri M; Fakhfakh R; Ghyoula M; Ben Abdallah M; Achour N
Tunis Med; 2000 Oct; 78(10):557-61. PubMed ID: 11190738
[TBL] [Abstract][Full Text] [Related]
5. [Costs and effects of alternative screening programs against cervical cancer].
Gyrd-Hansen D; Hølund B; Andersen P
Ugeskr Laeger; 1996 Aug; 158(35):4912-5. PubMed ID: 8801698
[TBL] [Abstract][Full Text] [Related]
6. An interim determination of health gain from oral cancer and precancer screening: 2. Developing a model of population screening.
Downer MC; Jullien JA; Speight PM
Community Dent Health; 1997 Dec; 14(4):227-32. PubMed ID: 9458580
[TBL] [Abstract][Full Text] [Related]
7. Cost effectiveness of population screening and rescreening for cervical cancer in the Netherlands.
Boon ME; de Graaff Guilloud JC
Acta Cytol; 1981; 25(5):539-42. PubMed ID: 6792845
[TBL] [Abstract][Full Text] [Related]
8. Cost of screening for cancerous and precancerous lesions of the cervix.
Méréa E; Le Galès C; Cochand-Priollet B; Cartier I; de Crémoux P; Vacher-Lavenu MC; Vielh P; Coste J
Diagn Cytopathol; 2002 Oct; 27(4):251-7. PubMed ID: 12357505
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of a hospital based cytology screening programme for reduction in life time risk of cervical cancer.
Agarwal SS; Murthy NS; Sharma S; Sharma KC; Das DK
Neoplasma; 1995; 42(2):93-6. PubMed ID: 7617084
[TBL] [Abstract][Full Text] [Related]
10. Does the increased sensitivity of the new Papanicolaou (Pap) tests improve the cost-effectiveness of screening for cervical cancer?
Reust CE
J Fam Pract; 2001 Feb; 50(2):175. PubMed ID: 11219567
[No Abstract] [Full Text] [Related]
11. [Population screening for uterine cervix cancer: the negative effects of insufficient knowledge as to what is normal and abnormal].
van der Graaf Y
Ned Tijdschr Geneeskd; 2002 Aug; 146(34):1569-71. PubMed ID: 12224477
[TBL] [Abstract][Full Text] [Related]
12. Cervical cancer screening program of Paraná: cost-effective model in a developing country.
Bleggi Torres LF; Werner B; Totsugui J; Collaço LM; Araújo SR; Huçulak M; Boza EJ; Fischer RM; De Laat L; Sobbania LC; Raggio A
Diagn Cytopathol; 2003 Jul; 29(1):49-54. PubMed ID: 12827718
[TBL] [Abstract][Full Text] [Related]
13. Policy analysis of cervical cancer screening strategies in low-resource settings: clinical benefits and cost-effectiveness.
Goldie SJ; Kuhn L; Denny L; Pollack A; Wright TC
JAMA; 2001 Jun; 285(24):3107-15. PubMed ID: 11427139
[TBL] [Abstract][Full Text] [Related]
14. Cervical screening in general practice: call and recall.
Ridsdale LL
J R Coll Gen Pract; 1987 Jun; 37(299):257-9. PubMed ID: 3129556
[TBL] [Abstract][Full Text] [Related]
15. Economic aspects of screening for cervical cancer in New Zealand.
Bethwaite J; Rayner T; Bethwaite P
N Z Med J; 1986 Oct; 99(811):747-51. PubMed ID: 3464889
[TBL] [Abstract][Full Text] [Related]
16. Improving the sensitivity of cervical cytology: what are the issues?
Myers ER
Am J Manag Care; 2000 Jul; 6(7):838-40. PubMed ID: 11067380
[No Abstract] [Full Text] [Related]
17. De novo establishment and cost-effectiveness of Papanicolaou cytology screening services in the Socialist Republic of Vietnam.
Levin CE; Sellors JW
Cancer; 2002 Apr; 94(8):2312-4; author reply 2314-6. PubMed ID: 12001136
[No Abstract] [Full Text] [Related]
18. Prospects for newer technologies in cervical cancer screening programmes.
Hailey DM; Lea R
J Qual Clin Pract; 1995 Sep; 15(3):139-45. PubMed ID: 8528539
[TBL] [Abstract][Full Text] [Related]
19. Costs and effectiveness of alternative strategies for cervical cancer screening in military beneficiaries.
Maxwell GL; Carlson JW; Ochoa M; Krivak T; Rose GS; Myers ER
Obstet Gynecol; 2002 Oct; 100(4):740-8. PubMed ID: 12383543
[TBL] [Abstract][Full Text] [Related]
20. Increasing women's participation in Pap smear screening in Australia--how can we tell if the national policy is effective?
Shelley J; Street A
Aust Health Rev; 1992; 15(2):190-9. PubMed ID: 10119050
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
